Overview of the pregnancy component of the GEM cluster randomized trial.

<p>Overview of the pregnancy component of the GEM cluster randomized trial.</p

Adjusted rate ratios from log multinomial regression estimating the association between perceived stress level and exceeding or being below the IOM recommendation for total GWG; Gestational Diabetes Effects’ on Mom study.

<p>Adjusted rate ratios from log multinomial regression estimating the association between perceived stress level and <u>exceeding or being below</u> the IOM recommendation for total GWG; Gestational Diabetes Effects’ on Mom study.</p

Demographic characteristics by perceived stress scale (PSS) score; Gestational Diabetes Effects’ on Mom (GEM) study.

<p>Demographic characteristics by perceived stress scale (PSS) score; Gestational Diabetes Effects’ on Mom (GEM) study.</p

Baseline characteristics in relation to any fracture before breast cancer (BC) diagnosis in aromatase inhibitor (AI) users.

<p>NOTE: Pharmacy data through December 31, 2013.</p>1<p> Logistic regression adjusted for age, race/ethnicity, menopausal status, and year of breast cancer diagnosis.</p>2<p> Median (physical activity) = 20.9 metabolic equivalent (MET)-hours/week; median (alcohol intake) = 3.1 g/day.</p><p>Baseline characteristics in relation to any fracture before breast cancer (BC) diagnosis in aromatase inhibitor (AI) users.</p

Baseline characteristics of study cohort by initial use of aromatase inhibitor (AI) or tamoxifen (TAM).

<p>NOTE: Pharmacy data through December 31, 2013; Missing data for entire cohort: menopausal status (n = 9), BMI (n = 28), smoking (n = 13), alcohol (n = 552), vitamin supplements (n = 37).</p>1<p> Logistic regression adjusted for age at breast cancer diagnosis as a continuous variable.</p>2<p> Median (overall) = 3.10 g/day, median (postmenopausal women) = 2.90 g/day.</p>3<p> Osteoporosis defined by ICD-9 code (733.00–733.09) or any prior bisphosphonate prescription.</p>4<p> Major fracture includes fracture of spine, humerus, wrist, or hip.</p><p>Baseline characteristics of study cohort by initial use of aromatase inhibitor (AI) or tamoxifen (TAM).</p

Baseline characteristics in relation to osteoporosis¹ before breast cancer diagnosis (BC) in aromatase inhibitor (AI) users.

<p>NOTE: Pharmacy data through December 31, 2013.</p>1<p> Osteoporosis defined by ICD-9 code (733.00–733.09) or any prior bisphosphonate prescription.</p>2<p> Logistic regression adjusted for age, race/ethnicity, menopausal status, and year of breast cancer diagnosis.</p>3<p> Median (physical activity) = 20.9 metabolic equivalent (MET)-hours/week; median (alcohol intake) = 3.1 g/day.</p><p>Baseline characteristics in relation to osteoporosis^{<a href="http://www.plosone.org/article/info:doi/10.1371/journal.pone.0111477#nt107" target="_blank">1</a>} before breast cancer diagnosis (BC) in aromatase inhibitor (AI) users.</p

Baseline characteristics in relation to major fracture¹ before breast cancer (BC) diagnosis in aromatase inhibitor (AI) users.

<p>NOTE: Pharmacy data through December 31, 2013.</p>1<p> Major fracture includes fracture of spine, humerus, wrist, or hip.</p>2<p> Logistic regression adjusted for age, race/ethnicity, menopausal status, and year of breast cancer diagnosis.</p>3<p> Median (physical activity) = 20.9 metabolic equivalent (MET)-hours/week; median (alcohol intake) = 3.1 g/day.</p><p>Baseline characteristics in relation to major fracture^{<a href="http://www.plosone.org/article/info:doi/10.1371/journal.pone.0111477#nt114" target="_blank">1</a>} before breast cancer (BC) diagnosis in aromatase inhibitor (AI) users.</p